<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00908960</url>
  </required_header>
  <id_info>
    <org_study_id>08-378</org_study_id>
    <nct_id>NCT00908960</nct_id>
  </id_info>
  <brief_title>Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles</brief_title>
  <acronym>MicroTEC</acronym>
  <official_title>A Randomized Controlled Trial of Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>North Shore Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VA Boston Healthcare System</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Research studies have shown a strong association between cancer and blood clots in the veins
      (also known as deep vein thrombosis). These blood clots can flow to the lungs (pulmonary
      embolism) which in severe cases may be life threatening. The purpose of this research study
      is to see if enoxaparin is effective in preventing blood clots in the veins in participants
      who have cancer of the pancreas, colorectal, non-small cell lung, ovary, or gastric and also
      have high levels of tissue factor bearing microparticles in their blood (TFMP). TFMP are
      small particles that are generated from different types of blood cells in the body. In people
      who have cancer, TFMP are thought to be generated from cancer cells and may represent a risk
      factor for deep vein thrombosis. Enoxaparin has been used to prevent formation of blood clots
      in patients after abdominal or orthopedic surgery and in patients who suffer from a severe
      medical illness. Based on these studies, we are investigating to see if it prevents
      thrombosis in people with certain types of cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was a randomized phase II trial to evaluate the cumulative incidence of VTE in
      cancer outpatients. At baseline, measurement of tissue factor-bearing microparticles (TFMP)
      was performed by impedance-based flow cytometry based on established methods. (Zwicker et al,
      2009) Patients were classified as having high or low TFMP levels based on a reference
      repository of plasmas from sixty cancer patients. The top tercile of tissue factor-bearing
      microparticle concentrations from the reference specimens (3.5 x 104 microparticles/Âµl) was
      considered a cutoff for &quot;high&quot; and corresponds with previously described &quot;detectable&quot; levels.
      Patients with high levels were randomized (2:1) to enoxaparin 40 mg subcutaneously once daily
      or observation. Randomization was stratified based on cancer diagnosis. Low TFMP patients
      were observed without anticoagulation. Both the treating physicians and patients were blinded
      to microparticle status in the observation arms.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2-Month Cumulative Incidence of VTE</measure>
    <time_frame>Assessment with lower extremity ultrasound occured at day 60/ month 2</time_frame>
    <description>2-month cumulative incidence of venous thromboembolism (VTE) is the probability of experiencing within 2 months of study entry the following events: any symptomatic proximal or distal lower extremity deep vein thrombosis, symptomatic pulmonary embolism or fatal pulmonary embolism diagnosed by autopsy, or asymptomatic proximal deep vein thrombosis diagnosed by screening compression ultrasound.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Major Hemorrhage Events</measure>
    <time_frame>Assessed during the 60 day therapy</time_frame>
    <description>Incidence is the number of patients experiencing at least one major hemorrhage events as defined according to International Society on Thrombosis and Haemostasis (ISTH) guidelines. (Schulman and Kearon 2005)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Assessed up to approximately 30 months</time_frame>
    <description>Overall survival is defined as the time from study entry to death or date last known alive and estimated using Kaplan-Meier (KM) methods.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Advanced Pancreatic, Colon, Lung, Gastric and Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>High TFMP: Enoxaparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received enoxaparin 40 mg subcutaneously once daily for 2 months (60 days).Only patients with high TFMP status at baseline were randomized to treatment or observation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High TFMP: Observation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients undergo observation until evaluation with a lower extremity ultrasound at 2 months (day 60). Only patients with high TFMP status at baseline were randomized to treatment or observation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low TFMP: Observation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients undergo observation until evaluation with a lower extremity ultrasound at 2 months (day 60). Patients with low TFMP status at baseline were directly assigned to observation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <arm_group_label>High TFMP: Enoxaparin</arm_group_label>
    <other_name>Lovenox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed malignancy that is metastatic or unresectable and for which
             standard curative therapies do not exist. Eligible malignancies include:

               -  Adenocarcinoma of the pancreas (locally advanced or metastatic)

               -  Colorectal (stage IV)

               -  Non-small cell lung (unresectable stage III or IV)

               -  Relapsed ovarian or stage IV

               -  Surgically unresectable or metastatic gastric adenocarcinoma

          -  First or second line therapy (within 4 weeks of initiating therapy).

          -  Minimum age 18 years

          -  Life expectancy of greater than 6 months

          -  ECOG Performance Status 0, 1, or 2 (Karnofsky 60% or greater).

          -  Participants must have normal organ and marrow function as outlined in the protocol.

        Exclusion Criteria:

          -  Participants may not be receiving any other study agents.

          -  Known brain metastases should be excluded from this clinical trial because of their
             poor prognosis and higher potential for intracranial hemorrhage.

          -  Prior history of documented venous thromboembolic event or pulmonary embolism within
             the last 5 years years (excluding central line associated events whereby patients
             completed anticoagulation &gt; 3 months previously)

          -  Active bleeding or high risk for bleeding (e.g. known acute gastrointestinal ulcer)

          -  Any history of significant hemorrhage (requiring hospitalization or transfusion)
             outside of a surgical setting within the last 5 years

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to enoxaparin or heparin.

          -  History of heparin-induced thrombocytopenia

          -  Presence of coagulopathy (PT or PTT&gt; 1.5 x upper limit of normal)

          -  Familial bleeding diathesis

          -  Known diagnosis of disseminated intravascular coagulation

          -  Currently receiving anticoagulant therapy

          -  Current use of aspirin (&gt;81mg daily), Clopidogrel (Plavix), cilostazol (Pletal),
             aspirin-dipyridamole (Aggrenox), or regular use of non-steroidal anti-inflammatory
             agents more than twice weekly. Maximum dose of ibuprofen is 400mg no more than twice
             per week.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Zwicker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Southern California-Keck School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Boston Healthcare System</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mass General/North Shore Cancer Center</name>
      <address>
        <city>Danvers</city>
        <state>Massachusetts</state>
        <zip>01923</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Zwicker JI, Liebman HA, Bauer KA, Caughey T, Campigotto F, Rosovsky R, Mantha S, Kessler CM, Eneman J, Raghavan V, Lenz HJ, Bullock A, Buchbinder E, Neuberg D, Furie B. Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study). Br J Haematol. 2013 Feb;160(4):530-7. doi: 10.1111/bjh.12163. Epub 2012 Dec 13.</citation>
    <PMID>23240761</PMID>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2009</study_first_submitted>
  <study_first_submitted_qc>May 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2009</study_first_posted>
  <results_first_submitted>July 22, 2013</results_first_submitted>
  <results_first_submitted_qc>October 22, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 12, 2013</results_first_posted>
  <last_update_submitted>November 22, 2017</last_update_submitted>
  <last_update_submitted_qc>November 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Jeffrey Zwicker, MD</investigator_full_name>
    <investigator_title>Attending Physician</investigator_title>
  </responsible_party>
  <keyword>enoxaparin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboplastin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>High TFMP: Enoxaparin</title>
          <description>Patients received enoxaparin 40 mg subcutaneously once daily for 2 months (60 days). Only patients with high TFMP status at baseline were randomized to treatment or observation.</description>
        </group>
        <group group_id="P2">
          <title>High TFMP: Observation</title>
          <description>Patients undergo observation until evaluation with lower extremity ultrasound at 2 months (day 60). Only patients with high TFMP status at baseline were randomized to treatment or observation.</description>
        </group>
        <group group_id="P3">
          <title>Low TFMP: Observation</title>
          <description>Patients undergo observation until evaluation with lower extremity ultrasound at 2 months (day 60). Patients with low TFMP status at baseline were directly assigned to observation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Evaluable</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Presence VTE dx or Absent VTE eval</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The analysis dataset is comprised of all evaluable patients.</population>
      <group_list>
        <group group_id="B1">
          <title>High TFMP: Enoxaparin</title>
          <description>Patients received enoxaparin 40 mg subcutaneously once daily for 2 months (60 days).
Only patients with high TFMP status at baseline were randomized to treatment or observation.</description>
        </group>
        <group group_id="B2">
          <title>High TFMP: Observation</title>
          <description>Patients undergo observation until evaluation with lower extremity ultrasound at 2 months (day 60). Only patients with high TFMP status at baseline were randomized to treatment or observation.</description>
        </group>
        <group group_id="B3">
          <title>Low TFMP: Observation</title>
          <description>Patients undergo observation until evaluation with lower extremity ultrasound at 2 months (day 60). Patients with low TFMP status at baseline were directly assigned to observation.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="32"/>
            <count group_id="B4" value="66"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.3" spread="10.5"/>
                    <measurement group_id="B2" value="63.4" spread="15.0"/>
                    <measurement group_id="B3" value="63.3" spread="11.7"/>
                    <measurement group_id="B4" value="64.0" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>2-Month Cumulative Incidence of VTE</title>
        <description>2-month cumulative incidence of venous thromboembolism (VTE) is the probability of experiencing within 2 months of study entry the following events: any symptomatic proximal or distal lower extremity deep vein thrombosis, symptomatic pulmonary embolism or fatal pulmonary embolism diagnosed by autopsy, or asymptomatic proximal deep vein thrombosis diagnosed by screening compression ultrasound.</description>
        <time_frame>Assessment with lower extremity ultrasound occured at day 60/ month 2</time_frame>
        <population>The analysis dataset is comprised of all evaluable patients.</population>
        <group_list>
          <group group_id="O1">
            <title>High TFMP: Enoxaparin</title>
            <description>Patients received enoxaparin 40 mg subcutaneously once daily for 2 months (60 days). Only patients with high TFMP status at baseline were randomized to treatment or observation.</description>
          </group>
          <group group_id="O2">
            <title>High TFMP: Observation</title>
            <description>Patients undergo observation until evaluation with lower extremity ultrasound at 2 months (day 60). Only patients with high TFMP status at baseline were randomized to treatment or observation.</description>
          </group>
          <group group_id="O3">
            <title>Low TFMP: Observation</title>
            <description>Patients undergo observation until evaluation with lower extremity ultrasound at 2 months (day 60). Patients with low TFMP status at baseline were directly assigned to observation.</description>
          </group>
        </group_list>
        <measure>
          <title>2-Month Cumulative Incidence of VTE</title>
          <description>2-month cumulative incidence of venous thromboembolism (VTE) is the probability of experiencing within 2 months of study entry the following events: any symptomatic proximal or distal lower extremity deep vein thrombosis, symptomatic pulmonary embolism or fatal pulmonary embolism diagnosed by autopsy, or asymptomatic proximal deep vein thrombosis diagnosed by screening compression ultrasound.</description>
          <population>The analysis dataset is comprised of all evaluable patients.</population>
          <units>percent probability</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" lower_limit="0" upper_limit="16.6"/>
                    <measurement group_id="O2" value="27.2" lower_limit="0" upper_limit="55.1"/>
                    <measurement group_id="O3" value="7.2" lower_limit="0" upper_limit="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.06</p_value>
            <method>Fine and Gray regression</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>6.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.03</ci_lower_limit>
            <ci_upper_limit>43.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Major Hemorrhage Events</title>
        <description>Incidence is the number of patients experiencing at least one major hemorrhage events as defined according to International Society on Thrombosis and Haemostasis (ISTH) guidelines. (Schulman and Kearon 2005)</description>
        <time_frame>Assessed during the 60 day therapy</time_frame>
        <population>The analysis dataset is comprised of evaluable patients.</population>
        <group_list>
          <group group_id="O1">
            <title>High TFMP: Enoxaparin</title>
            <description>Patients received enoxaparin 40 mg subcutaneously once daily for 2 months (60 days). Only patients with high TFMP status at baseline were randomized to treatment or observation.</description>
          </group>
          <group group_id="O2">
            <title>High TFMP: Observation</title>
            <description>Patients undergo observation until evaluation with lower extremity ultrasound at 2 months (day 60). Only patients with high TFMP status at baseline were randomized to treatment or observation.</description>
          </group>
          <group group_id="O3">
            <title>Low TFMP: Observation</title>
            <description>Patients undergo observation until evaluation with lower extremity ultrasound at 2 months (day 60). Patients with low TFMP status at baseline were directly assigned to observation.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Major Hemorrhage Events</title>
          <description>Incidence is the number of patients experiencing at least one major hemorrhage events as defined according to International Society on Thrombosis and Haemostasis (ISTH) guidelines. (Schulman and Kearon 2005)</description>
          <population>The analysis dataset is comprised of evaluable patients.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Overall survival is defined as the time from study entry to death or date last known alive and estimated using Kaplan-Meier (KM) methods.</description>
        <time_frame>Assessed up to approximately 30 months</time_frame>
        <population>The analysis dataset is comprised of all evaluable patients.</population>
        <group_list>
          <group group_id="O1">
            <title>High TFMP: Enoxaparin</title>
            <description>Patients received enoxaparin 40 mg subcutaneously once daily for 2 months (60 days). Only patients with high TFMP status at baseline were randomized to treatment or observation.</description>
          </group>
          <group group_id="O2">
            <title>High TFMP: Observation</title>
            <description>Patients undergo observation until evaluation with lower extremity ultrasound at 2 months (day 60). Only patients with high TFMP status at baseline were randomized to treatment or observation.</description>
          </group>
          <group group_id="O3">
            <title>Low TFMP: Observation</title>
            <description>Patients undergo observation until evaluation with lower extremity ultrasound at 2 months (day 60). Patients with low TFMP status at baseline were directly assigned to observation.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival is defined as the time from study entry to death or date last known alive and estimated using Kaplan-Meier (KM) methods.</description>
          <population>The analysis dataset is comprised of all evaluable patients.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.8" lower_limit="5.2" upper_limit="30"/>
                    <measurement group_id="O2" value="11.8" lower_limit="5.4" upper_limit="18.2"/>
                    <measurement group_id="O3" value="17.3" lower_limit="10.3" upper_limit="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Assessed during the 60 day therapy</time_frame>
      <group_list>
        <group group_id="E1">
          <title>High TFMP: Enoxaparin</title>
          <description>Patients received enoxaparin 40 mg subcutaneously once daily for 2 months (60 days).
Only patients with high TFMP status at baseline were randomized to treatment or observation.</description>
        </group>
        <group group_id="E2">
          <title>High TFMP: Observation</title>
          <description>Patients undergo observation until evaluation with lower extremity ultrasound at 2 months (day 60). Only patients with high TFMP status at baseline were randomized to treatment or observation.</description>
        </group>
        <group group_id="E3">
          <title>Low TFMP: Observation</title>
          <description>Patients undergo observation until evaluation with lower extremity ultrasound at 2 months (day 60). Patients with low TFMP status at baseline were directly assigned to observation.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Platelets</sub_title>
                <description>Subject with lung cancer on lovenox and was found with low platelets. Another subject with colon cancer on observation was also found with low platelets.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>elevated troponin</sub_title>
                <description>A pancreatic cancer subject on observation arm with elevated troponin</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI-Hemorrhage</sub_title>
                <description>Study subject with pancreatic cancer on the observation arm died following an gastrointestinal bleed.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <description>A pancreatic cancer subject on observation arm died following a blood infection.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Disease progression</sub_title>
                <description>These subjects had disease progression: 3 Lung cancer on observation; 1 pancreatic cancer on observation; 1 pancreatic cancer on lovenox and another lung cancer on lovenox.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Alkaline Phosphotase and aspartate aminotransferase</sub_title>
                <description>Subject with pancreatic cancer and on lovenox was hospitalized for a decreased urine output, obstructive liver function tests, and ankle edema.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphatics</sub_title>
                <description>Subject with lung cancer and on lovenox was hospitalized with increased swelling and discomfort over left side of neck.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 10.0">Dyspnea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>A subject with lung cancer on the observation arm experienced shortness of breath while on trial. Another study subject with pancreatic cancer on the observation arm died following rapidly progressive shortness of breath and hypoxia at nursing home.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>pneumonia and anemia</sub_title>
                <description>subject with pancreatic cancer on lovenox arm was hospitalized for pneumonia and anemia.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jeffrey Zwicker, MD</name_or_title>
      <organization>Beth Israel Deaconess Medical Center</organization>
      <phone>617-667-9299</phone>
      <email>jzwicker@bidmc.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

